Kornimate/medical-research-clean huggingface dataset:
limb remote ischemic conditioning and cerebrovascular reserve

Conditions: Ischemic Cerebrovascular Disease

Summary: cerebrovascular reserve (cvr), defined as the increase in cerebral blood flow (cbf)in response to a vasodilatory stimulus, is known to reflect the compensative capacity of the brain to maintain adequate blood flow in the face of decreased perfusion due to arterial stenosis. cvr dysfunction has been identified as an independent risk factor for ischemic stroke. limb remote ischemic preconditioning （lric) has been suggested as a protective therapeutic modality against brain ischemia. so it is worth to detect whether lric can improve the cvr ability in ischemic cerebrovascular disease patients.


Eligibility criteria:
inclusion criteria: - (1)symptomatic intracranial arterial stenosis measuring \>=50% by angiography or \>=70% by ultrasound, ct angiography (cta), or magnetic resonance angiography (mra);(2)age range 18-80 years;(3)compared with normal brain tissue, the reduction of cerebral glucose metabolism (cgm) and/ or cerebral blood flow (cbf) in the focal area\>=8%;(4)stable vital signs, normal renal and hepatic functions; (5)no hemorrhagic tendency;(6)subject or his or her legally authorized representative was able to provide an informed conised. exclusion criteria: -(1)uncontrolled hypertension (defined as systolic blood pressure\>=200 mmhg despite medications at enrollment); (2)any vascular, soft tissue, or orthopedic injury (eg, superficial wounds and fractures of the arm) that contraindicated bilateral arm ischemic preconditioning;(3)peripheral vascular disease (especially subclavian arterial and upper limb artery stenosis or occlusion); (4)hematologic disease;(5)severe or unstable concomitant disease;(6)can not tolerate lric treatment;(7)no informed consent.

Keywords: limb remote ischemic conditioning cerebrovascular reserve
evaluation of the functional outcomes after bilateral, 3d ultrasound-guided focal thermal ablation of the prostate transition zone, in patients with benign prostatic hyperplasia-related obstruction

Conditions: Benign Prostatic Hyperplasia

Summary: the aim of the current study is to evaluate the efficacy of transperineal focal microwave ablation (tma) of the prostate transition zone as a new treatment for lower urinary tract symptoms (luts) due to benign prostatic hyperplasia (bph) within a prospective single-institutional pilot study.

transurethral resection of the prostate, laser vaporization or enucleation, and simple open prostatectomy represent the current gold standard surgical interventions for bph-related obstruction. however, these treatments are burdened by their invasiveness, intra and post-operative morbidity, and long-term complications, including ejaculatory dysfunction (70%), urethral strictures (7%), urinary incontinence (2%), and bleeding. laser-based surgical strategies have only partially overcome these drawbacks. to provide a personalized therapy for the treatment of bph related-symptoms, several minimally invasive surgical therapies (mists) were developed with the aim of achieving outcomes comparable to the gold standard invasive procedures while minimizing sd and other complications. urolift implants and rezum system have demonstrated less complication rate and hospitalization time than standard surgeries. recently, 3d ultrasound-guided transperineal focal microwave ablation (tma) was developed as a focal treatment for localized prostate cancer. ultrasound-mri image fusion was performed with organ-based tracking-registration using koelis trinity™ (koelis, meylan, france). microwave thermal ablation was provided by the tato generator (biomedical srl, firenze, italy) using a single 17g needle inserted transperineally. this treatment was reported to be safe, precise, and feasible in an outpatient setting.

Eligibility criteria:
inclusion criteria: * man over 40 years old * indication of surgical management for bph * prostate volume ≥30 cc and ≤100 cc as evaluated by ultrasonography * ipss score ≥15 * qmax ≤12 ml/s * affiliated to the french national social security system * patient suitable for iv sedation or general anesthesia and focal microwave ablation * wish and able to comply with planned visits * able to express his consent * signed informed consent form exclusion criteria: * unwillingness to accept the treatment * neurological pathology responsible for micturition disorders * history of prostatic surgery * history of prostatic arterial embolization * prostate protrusion index of grade 2 (\>5 mm) or more as evaluated by ultrasonography. * stenosis of the urethra * history of prostate cancer * history of radiotherapy or pelvic surgery * life expectancy \<2 years * inability to understand the informed consent document, to give consent voluntarily or to complete the study tasks. * participation in another clinical study involving an investigational product within 1 month before study entry.

Keywords: benign prostatic hyperplasia
a study in the use of home blood pressure monitoring and telephone follow-up to control blood pressure

Conditions: Hypertension

Summary: the purpose of this study is to determine if the use of home blood pressure monitors plus nurse telephone monitoring is more effective than the use of blood pressure monitors alone in improving control of high blood pressure in an urban medical clinic.

participants will all have home blood pressure monitors, education session on controlling their blood pressure and will be randomized to recieve 6 months of intensive telephonic on a set monitoring schedule or no telephonic follow up. phone calls will be weekly for 4 weeks, then every 2 weeks for 8 weeks then monthly for 3 months.

Eligibility criteria:
inclusion criteria: * diagnosed with essential hypertension * systolic blood pressure \>140 mm hg (130 if diabetic) or diastolic blood pressure \> 90 mm hg (80 if diabetic)on at least 2 clinic visits prior to randomization * bp at time of screening is \> than systolic 140 (130 if diabetic) or diastolic 90 (80 if diabetic) * patient is prescribed at least 1 antihypertensive medication * patient is fluent in english * patient is easily accessible by telephone exclusion criteria: * persons with stage 4 or 5 chronic kidney disease or end stage renal disease on dialysis * patients with a terminal illness * patients with severe dementia or serious mental illness * inability to preform self blood pressure monitoring * patient lacks a functioning home phone or personal cellular phone * pregnant or planning to get pregnant * arm circumference exceeds the allowable limit on the largest home bp monitor cuff

Keywords: hypertension home blood pressure monitoring nurse telephone follow up medically underserved populations
radiolabeled glass beads used for treating patients with primary liver cancer when surgery is not an option

Conditions: Liver Cancer; Hepatoma

Summary: fewer than 15% of hepatoma patients are suitable candidates for surgical removal of their cancer. the purpose of this protocol is to provide supervised access at oregon health and science university to y-90 treatment to provide these patients access to an alternate therapy. the radioactive beads are placed directly near or into the liver tumor with the intention of destroying the tumor cells.

patients receive y-90 (yttrium) glass microspheres via percutaneous hepatic arterial infusion. patients amy be retreated between 30-90 days after initial infusion. after completion of therapy, patients are followed for 30 days and then every 3 months for up to 2 years.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of hcc * cancer is unresectable * ecog score 0-2 * age of 18 yrs or over * able to give consent exclusion criteria: * contraindication to angiography and selective visceral catheterization * portal hypertension with portal venous shunt away from the liver * evidence of potential delivery of \> 16.5 mci of radiation to the lungs * evidence of any detectable tc-99m maa flow to the stomach or duodenum, after application of established angiographic techniques to stop such flow * significant extrahepatic disease representing an imminent life-threatening outcome * severe liver dysfunction or pulmonary insufficiency * active uncontrolled infection * significant underlying medical or psychiatric illness * pregnancy

Keywords: liver tumor cancer hepatoma yttrium
textbook outcome in adrenal neoplasms

Conditions: Outcome Assessment; Adrenal Neoplasm

Summary: background: textbook outcome (to) is a multidimensional quality management tool that uses a set of traditional surgical measures to reflect an "ideal" surgical result for a particular pathology. the aim of the present study is to record the rate of to in patients undergoing elective surgery for adrenal neoplasms. material and methods: retrospective study of all patients undergoing scheduled adrenal neoplasms surgery at a spanish university hospital from september january 2010 to december 2022. emergency surgeries were excluded. the variables included in the definition of to were: r0 resection, no clavien-dindo ≥iiia complications, no prolonged stay, no readmissions, and no mortality in the first 30 days. the main objective of this study is to analyse the achievement of to in a series of patients undergoing scheduled adrenal neoplasms resection at the doctor balmis general university hospital in alicante, spain. the investigators compare the group of patients who achieve a to result with the group of patients who do not. a univariable and multivariable analysis will be carry out in order to indentified the variables associated with to.


Eligibility criteria:
inclusion criteria: * patients undergoing elective adrenal resection were eligible for the study exclusion criteria: * age under 18 years * emergency surgery * resections of other organs in the same surgery.
verifynow french registry

Conditions: Stent Thrombosis; Clopidogrel; Aspirin; Bleeding; Angioplasty

Summary: the purpose of this study is to determine the effect of clopidogrel or aspirin reactivity as measured by a point-of-care platelet function assay on thrombotic or bleeding events after percutaneous coronary intervention (pci) with drug eluting or bare metal stent. methods: platelet reactivity on clopidogrel and aspirin therapy is measured before pci with verifynow (accumetrics inc.,san diego, ca, usa) p2y12 or aspirin assay respectively in 1000 consecutive patients from 20 centers in france undergoing coronary angioplasty with stent. exclusion criteria are: acute myocardial infarction, treatment with vitamin k antagonists and the use of antigp2b3a before pci. all patients are pre-treated with clopidogrel and aspirin. non-response to aspirin or clopidogrel is determined according to the result of the verifynow assay (cut off : \ 550 aru for aspirin). the primary end point is the occurrence of definite or probable stent thrombosis (arc definition) and the secondary end-points include global and cardio-vascular mortality, non fatal myocardial infarction and major bleeding. a clinical evaluation is scheduled at discharge and by telephone contact at one month and one year.


Eligibility criteria:
inclusion criteria: * coronary angioplasty with stent exclusion criteria: * use of agp2b3a * acute myocardial infarction * no aspirin and clopidogrel pretreatment * use of avk * aspirin or clopidogrel contre-indication

Keywords: stent thrombosis clopidogrel aspirin bleeding coronary angioplasty
daily monitoring of exhaled nitric oxide in asthmatic patients

Conditions: Asthma

Summary: previous studies have demonstrated that exhaled nitric oxide can be useful to monitor the efficacy of anti-inflammatory treatment as well as to predict a risk of asthma relapse in asthmatic patients. the aim of the present study is to evaluate the time course of exhaled nitric oxide in mild asthmatic patients, stopping regular treatment with inhaled corticosteroids, if it is possible, in relationship with symptoms and lung function.

all patients were evaluated with pulmonary lung function, exhaled nitric oxide and peak expiratory flow (pef) and fill in a personal diary for the first two weeks when patients are in treatment; the same evaluation will be made for other four weeks without treatment.

Eligibility criteria:
inclusion criteria: * mild asthmatic treated with low dose inhaled steroids for whom it has to be considered stop of steroid treatment according to gina guidelines exclusion criteria: * age \< 5 years * chronic respiratory diseases

Keywords: asthma exhaled nitric oxide lung function
foraminal enlargement and postoperative pain.

Conditions: Pain Postoperative

Summary: the purpose of this study is to determine whether enlarging the apical foramen causes postoperative pain in teeth with necrotic pulp and apical periodontitis.

foraminal enlargement (fe) is an intentional procedure that enlarges the cement canal. however, some rcts indicate that enlarging the fe causes postoperative pain, flare-up, and destroy the apical constriction, whilst some rcts pointed out there is no difference in terms of pain when a fe has been performed. the investigators, therefore, would like to conduct a rct to increase both sample size and the number of published studies to do a systematic review for this topic.

Eligibility criteria:
inclusion criteria: * mature permenent teeth having pulpal necrosis and apical periodontitis. exclusion criteria: * systemic disorders * diabetes * pregnancy * less than 18 years of age * immunocompromised * patients who had taken antibiotics in the past 1 month * patients who had a positive history of analgesic use within the past 3 days * previously accessed teeth

Keywords: foraminal enlargement root canal treatment
gilotrif (afatinib) in advanced non-small cell lung cancer patients pre-treated with erlotinib or gefitinib

Conditions: Non-small Cell Lung Cancer

Summary: the program will provide early access to the investigational drug gilotrif in patients with advanced non-small cell lung cancer who have failed at least 6 months on erlotinib or gefitinib. the compassionate use programme will also provide additional safety information on gilotrif use.


Eligibility criteria:
inclusion criteria: 1. patients with pathologically confirmed diagnosis of adenocarcinoma of the lung stage iv with progressive disease following at least one line of platinum-based cytotoxic chemotherapy 2. patients progressing after clinical benefit on erlotinib or gefitinib: clinical benefit is defined as stable disease for at least 6 months, or a complete or partial response, or the presence of an activating mutation of the epidermal growth factor (egf) receptor family. 3. no further treatment option is available. 4. male and female patients age ≥18 years. 5. written informed consent that is consistent with international conference on harmonisation-good clinical practice (ich-gcp) guidelines and local law. exclusion criteria: 1. significant or recent acute gastrointestinal disorders with diarrhoea as a major symptom. 2. patients who have any other life-threatening illness or organ system dysfunction, which in the opinion of the investigator, would compromise patient safety. 3. history of cardiac disease that is clinically significant, as judged by the investigator or uncontrolled cardiac disease (including congestive heart failure, angina, myocardial infarction, arrhythmia, including new york heart association (nyha) functional classification of 3). 4. aspartate amino transferase (ast) or alanine amino transferase (alt) ≥ three times the upper limit of normal (if related to liver metastases ≥ five times the upper limit of normal). 5. bilirubin ≥1.5 mg/dl 6. serum creatinine ≥ 1.5 times of the upper normal limit or calculated/measured creatine clearance ≤ 45ml/min 7. women of child-bearing potential or men who are able to father a child unwilling to use a medically acceptable method of contraception during the treatment. 8. pregnancy or breast feeding. 9. pre-existing interstitial lung disease (ild). 10. patients suitable to be included into afatinib clinical trials
study of safety, tolerability and pharmacokinetics of lna043 in japanese osteoarthritis participants

Conditions: Osteoarthritis; Knee

Summary: the objective of this study was to determine the safety, tolerability and pharmacokinetics after single ascending dose of lna043 in japanese participants with osteoarthritis of the knee.

this was a non-confirmatory, randomized, participant- and investigator-blinded, placebo-controlled, single ascending dose study to investigate the safety, tolerability and pk of lna043 in japanese participants with osteoarthritis of the knee. this study consisted of 2 cohorts with a total of 12 participants.

Eligibility criteria:
inclusion criteria: * male and female japanese participants aged 20 to 80 years at screening * a body mass index (bmi) 16.0 kg/m2 or more but less than 35.0 kg/m2 at screening * established diagnosis of primary tibio-femoral osteoarthritis of the target knee by standard american college of rheumatology (acr) criteria for at least 6 months prior to screening (clinical and radiological criteria). exclusion criteria: * partial or complete joint replacement in the target knee. planned knee surgery for either knee during the study. * arthroscopy of the target knee within 6 months prior to screening or planned during the study * use of electrotherapy, acupuncture, and/or chiropractic treatments for osteoarthritis of the knee within 4 weeks prior to screening * malalignment \>10° in the target knee (varus/valgus)

Keywords: osteoarthritis knee cartilage
clinical and radiographic evaluation of zirconomer restorative

Conditions: Dental Caries in Children; Dental Materials

Summary: is zirconomer restorative material more effective than a glass ionomer cement in restoration of primary molars

this trial seeks to evaluate the clinical and radiographic performance of two materials zirconomer restorative material and glass ionomer cement to achieve better treatment for primary molars.

Eligibility criteria:
* inclusion criteria: 1. children having carious primary molars(class1) without pulp exposure and normal radiograph. 2. children between age 5 and 7 years. 3. both male and female are included. 4. cooperative children. exclusion criteria: 1. patients with systemic diseases. 2. parent refuse to participate.

Keywords: gic/zirconomer
evaluation of accs100 to reduce aflatoxin exposure in kenya

Conditions: Aflatoxicosis

Summary: the purpose of this study is to pilot test the effectiveness, acceptability, and palatability of accs100 in a high-risk kenyan population.

aflatoxins are harmful by-products of the molds aspergillus flavus and a. parasiticus and are major contaminants of agricultural produce such as maize. acute aflatoxin exposure (i.e., aflatoxicosis) can lead to jaundice, vomiting, abdominal pain, and liver failure, with documented fatality rates as high as 40%. kenya experiences extreme aflatoxin exposure and fatal, recurring aflatoxicosis outbreaks. numerous clinical trials have found heat processed calcium dioctahedral smectite clay \[i.e., air classified calcium silicate (accs100)\] to be safe and effective in binding to aflatoxin to decrease bioavailability and subsequently reduce toxin-induced effects. the investigators propose to pilot test the effectiveness, acceptability, and palatability of accs100 in a high-risk kenyan population. if successful, accs100 could be scaled-up for use in kenya to prevent aflatoxin-associated mortality during high-risk periods. to accomplish this objective, the investigators will recruit fifty health adults into a crossover study. each participant will spend one week consuming accs100 and one week consuming a calcium carbonate placebo. daily first morning void urine samples will monitor effectiveness in reducing aflatoxin bioavailability, and periodic questionnaires will assess acceptance and palatability.

Eligibility criteria:
inclusion criteria: * adult ≥18 years of age * consumes corn- and/or peanut-derived foods at least four times per week * no plans to travel away from the household for more than one day in the next month exclusion criteria: * women who may be pregnant * history of medical illnesses * presence of protein or glucose in urine using chemstrip * does not provide informed consent

Keywords: aflatoxin kenya
hfnc vs lfnc in patients with af undergoing rfca under deep sedation.

Conditions: Deep Sedation; Oxygen Therapy; Radiofrequency Ablation

Summary: oxygen supplementation through high flow nasal cannula (hfnc) may reduce the incidence of desaturation and hypoxemia during deep sedation at radiofrequency catheter ablation (rfca procedures).this study is designed to test the hypothesis that the incidence of hypoxemia and desaturation in patients with atrial fibrillation undergoing rfca under deep sedation, is less when using hfnc as compared to use of standard low flow nasal cannula (lfnc).

desaturation may occur in patients under deep sedation which results in an elevated risk for perioperative adverse events including hypoxemia (1-3). the incidence of hypoxemia was 168 per 1000 in a general procedural sedation and analgesia population (4). the clinical significance of transient episodes of hypoxemia remains debatable. however, many peri-operative incidents are often short-term and limited in nature, but a number of them are a predictor to a serious complication with a permanent injury (5).this study investigates if high flow nasal cannula (hfnc) as compared to low flow nasal cannula (lfnc) will result in a lower incidence of intra-procedural oxygen desaturation and hypoxemia in patients with atrial fibrillation undergoing deep sedation for radiofrequency catheter ablation (rfca).

Eligibility criteria:
inclusion criteria: * adults undergoing an elective rfca for atrial fibrillation in the maastricht umc cardiac catheter labs under deep sedation administered by a clinician anesthesiology exclusion criteria: * age under 18 years * body mass index (bmi) \> 32 kg/m² * diagnosed sleep apnoea syndrome (sas) * chronic pulmonary obstructive disease (copd) gold iv and copd gold iii with frequent or recent exacerbation * diagnosed pulmonary or cardiac condition requiring chronic oxygen therapy * complete nasal obstruction * active nose bleeding * untreated pneumothorax (pre- existing) * recent upper airway surgery * recent base of skull fracture * expected difficult airway
hpv vaccination study in postpartum women

Conditions: HPV; Immunization; Human Papilloma Virus

Summary: the human papillomavirus (hpv) is the most common sexually transmitted infection (sti) in the united states (u.s.) and is responsible for a wide range of conditions, including cancers within the anogenital tract and the oropharynx. in just the u.s. alone, it's estimated that hpv causes 330,000 cases of precancerous cervical dysplasia and 12,000 cases of cervical cancer. the investigators propose a 2-dose hpv vaccination study in women seeking postpartum care at johns hopkins university. the investigators will measure the immunogenicity and acceptability of the vaccine in the postpartum setting.

this is a pilot, non-inferiority clinical trial using historical controls. participants will have whole blood drawn at 0 months, 6 months, and 7 months and receive the hpv vaccine at 0 months, 6 months, and 12 months. each blood draw will consist of one 15ml red top tube to measure hpv serologies and hormone levels. all blood samples collected will be analyzed at the end of the study.

Eligibility criteria:
inclusion criteria: * participants biologically born as females between the ages of 15 through 45 who have delivered a live born baby within the past 72 hours. exclusion criteria: * pregnancy * severe allergic reaction to vaccine components * prior receipt of an hpv vaccine dose * fetal demise or stillbirth * allergy to latex or yeast * moderate or severe acute illness (deemed by the investigator to exclude) * immunosuppression (e.g., hiv, solid organ transplant).

Keywords: human papilloma virus hpv immunization